ETFs Holding NLNK »    NLNK Historical Stock Prices »
NLNK News Video: Wed, Mar 29, 2017, 1:41 PM — Wednesday's ETF with Unusual Volume: FTLS

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
NewLink Genetics is a clinical-stage immuno-oncology company focused on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. These product candidates, indoximod, NLG802 and NLG919, are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer. Additional clinical-stage product candidates in Co.'s pipeline include two product candidates that utilize its HyperAcute® Cellular Immunotherapy technology and two small molecules. The HyperAcute Immunology candidates, tergenpumatucel-L and dorgenmeltucel-L, for patients with advanced lung cancer and melanoma, respectively. Self directed investors in NewLink Genetics Corp will be interested in keeping up with all NewLink Genetics Corp news they can find, both NLNK news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on NLNK. At RediNews, we simplify this task by presenting both NLNK news releases originating from NewLink Genetics Corp itself, and NLNK news from a variety of media outlets. Visitors can browse this news online and through our NLNK RSS news feed.


NLNK News — Articles, Videos, & Press Releases

Commit To Purchase NewLink Genetics Corp At $2, Earn 36.5% Annualized Using Options
Monday, April 1, 2019, 11:54 AM — Stock Options Channel
4 Small Biotech Stocks Likely to Witness More Upside in 2019
Friday, March 29, 2019, 8:36 AM — Zacks
Interesting NLNK Call Options For July 2019
Monday, December 24, 2018, 10:38 AM — Stock Options Channel
Analysts Predict 34% Gains Ahead For The Holdings of IBB
Wednesday, October 24, 2018, 7:35 AM — ETF Channel
First Week of January 2019 Options Trading For NewLink Genetics (NLNK)
Friday, September 7, 2018, 10:38 AM — Stock Options Channel
Commit To Purchase NewLink Genetics Corp At $4, Earn 28.4% Annualized Using Options
Wednesday, July 25, 2018, 11:48 AM — Stock Options Channel
NewLink Genetics Becomes Oversold (NLNK)
Tuesday, July 24, 2018, 4:23 PM — Dividend Channel
NLNK is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:


Consider RediNews RSS feeds to complement your web page financial content. Whether below a detailed quote page, a stock history chart, or featured on your home page, RediNews has an RSS feed to meet your needs. Integrate news by specific stock symbol, or an entire market sector. Simply navigate to any RediNews news page by specific ticker symbol, then click the RSS icon for any news page to reach the associated RSS feed (the icon will look like this): .

NLNK News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.